Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline Podcast: Part 1 (2020)

To encourage consistent, high quality, evidence-based treatment of patients, the AUA is launching a series of podcast episodes designed to improve the ability of the urologist to care for patients with prostate, bladder and kidney cancers. These activities are designed to increase the clinician’s competence in the application of new and emerging treatment options, including their mechanism of action and associated side effects.

Based on the documented need for additional education in prostate cancer, bladder cancer, and renal cell carcinoma, the AUA will identify expert faculty to engage in a series of ten interactive interview-style episodes. The 2020 AUA Expert Exchange Podcast: Discussions About Managing GU Cancer is designed to address very specific learning opportunities and reach urologists in an easy, flexible way with smaller, targeted updates. This activity will focus on the following topic: 

Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline Part 1



This educational series is supported by independent educational grants from:

  • Astellas
  • AstraZeneca
  • Bristol Myers Squibb
  • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Merck
  • Pfizer, Inc
  • Sanofi Genzyme
  • UroGen Pharma, Inc.


Target Audience

  • Urologists

Learning Objectives

At the conclusion of this activity, participants will be able to:

  1. Analyze breakthrough treatments in the management of advanced and metastatic hormone sensitive prostate cancer (mHSPC) and castration resistant prostate cancer (CRPC).
  2. Identify the active agents and their mechanism of action in the management of mHSPC, nmCRPC and mCRPC.
  3. Describe the indications, sequencing and combinations for treatment with approved agents in the management of mHSPC and nmCRPC.


Course summary
Available credit: 
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Non-Physician Participation
Course opens: 
Course expires: 

Education Council & COI Review Work Group Disclosures

File Education Council & COI Reviewer Disclosures.xlsx

AUA Office of Education Staff has nothing to disclose.

Podcast Co-Host(s)

Michael Cookson, MD,MHA

has a financial relationship (Independent contractor) with Myovant Sciences;.
has a financial relationship (Independent contractor) with Astellas Pharma, Inc.;.
has a financial relationship (Independent contractor) with Merck;.
has a financial relationship (Independent contractor) with Bayer Healthcare Pharmaceuticals;.
has a financial relationship (Independent contractor) with Ferring Pharmaceuticals;.
has a financial relationship (Independent contractor) with TesoRx Pharma LLC;.

Victor Nitti, MD

has a financial relationship (Stock) with Serenity Pharmeuticals;.


Learners will participate in this online educational activity by listening to the podcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.

Estimated time to complete this activity: 0.50 hours

Release Date: October, 2020
Expiration Date: October, 2021


The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


The American Urological Association designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.


It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.


All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.


All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty


The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Available Credit

  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Non-Physician Participation
Please login or register to take this course.